Results
eNauka >
Rezultati >
HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma- Overall survival analysis.
| Naziv: | HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma- Overall survival analysis. | Autori: | Maglakelidze, Marina; ...; (broj, koautora 16) | Godina: | 2023 | Publikacija: | JOURNAL OF CLINICAL ONCOLOGY | ISSN: | 0732-183X Journal of Clinical Oncology Pretraži identifikator |
Tip rezultata: | Konferencijski rad | Kolacija: | vol. 41 str. 289-289 | WoS-ID: | 001093994600366 | URI: | https://enauka.gov.rs/handle/123456789/866094 | Projekat: | Imugene Limited | Izvor metapodataka: | (Preuzeto iz Nasi u WoS) | M-kategorija: | Mp kategorija će biti prikazana naknadno. |
6
WEB OF SCIENCETM
Google ScholarTM
Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.